CEL-SCI Corporation (CVM) Starts Presentation at the 8th Annual LD Micro Invitational
CEL-SCI Corporation (NYSE: CVM) is a Phase 3 cancer immunotherapy company. The Phase 3 study is fully enrolled with 928 patients. When it comes to cancer immunotherapy, CEL-SCI believes it is most logical to boost the patient’s immune system while it is still intact in order to have the greatest possible impact on survival. Therefore, CEL-SCI treats patients who are newly diagnosed with head and neck cancer with its lead investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection), BEFORE they have received surgery, radiation and/or chemotherapy. For more information, visit the company's website at www.CEL-SCI.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information…